Mark Ng Tang Fui

Mark Ng Tang Fui

Auto-generated profile, based on publicly available information

Mark Ng Tang Fui

Department of Medicine Austin Health, University of Melbourne, Heidelberg, Australia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Asian Journal of Andrology
Verified
Journal Article
Open access
PDF file
MGMathis Grossmann
Mathis Grossmann
MFMarkNg Tang Fui
MarkNg Tang Fui
PDPhilippe Dupuis
Philippe Dupuis
With increasing modernization and urbanization of Asia, much of the future focus of the obesity epidemic will be in the Asian region. Low testosterone levels are frequently encountered in obese men who do not otherwise have a recognizable hypothalamic-pituitary-testicular (HPT) axis pathology. Moderate obesity predominantly decreases total testosterone due to insulin resistance-associated reductions in sex hormone binding globulin. More severe obesity is additionally associated with reductions in free testosterone levels due to suppression of the HPT axis. Low testosterone by itself leads to increasing adiposity, creating a self-perpetuating cycle of metabolic complications. Obesity-associated hypotestosteronemia is a functional, non-permanent state, which can be reversible, but this requires substantial weight loss. While testosterone treatment can lead to moderate reductions in fat mass, obesity by itself, in the absence of symptomatic androgen defi ciency, is not an established indication for testosterone therapy. Testosterone therapy may lead to a worsening of untreated sleep apnea and compromise fertility. Whether testosterone therapy augments diet- and exercise-induced weight loss requires evaluation in adequately designed randomized controlled clinical trials.

1 February 2005 in Cardiovascular Research
Verified
Journal Article
Closed access
SES Ellmark
S Ellmark
GDG Dusting
G Dusting
MNM Ngtangfui
M Ngtangfui
NGN Guzzopernell
N Guzzopernell
GDG Drummond
G Drummond
NADPH oxidases are important sources of reactive oxygen species (ROS) in the vasculature. In phagocytic cells, the catalytic subunit of NADPH oxidase is a glycoprotein, gp91phox. However, vascular smooth muscle cells (VSMCs), which show prominent NADPH oxidase activity, lack gp91phox. Hence, we examined the role of Nox4, a gp91phox homologue, in superoxide production in mouse-cultured VSMCs. Incubation of VSMCs with NADPH increased ROS production whether detected by lucigenin-enhanced chemiluminescence or dichlorofluorescein. Superoxide production was inhibited by the NADPH oxidase inhibitors, diphenyleneiodonium and apocynin, but not by inhibitors of other potential sources of superoxide. In unstimulated VSMCs, phosphorothioate antisense oligonucleotides against Nox4 down-regulated mRNA expression of the subunit by 65% and attenuated superoxide production by 41% without affecting Nox1 expression. Interleukin-1beta (IL-beta) thrombin and platelet-derived growth factor (PDGF) also reduced Nox4 mRNA expression after 3 h without affecting Nox1 levels. Of these stimuli, only IL-beta reduced superoxide, but this effect was more rapid (< or =30 min) than its actions on Nox4. Under resting conditions, NADPH oxidase activity in VSMCs is largely dependent upon Nox4 expression. Proinflammatory mediators down-regulated Nox4 but did not affect Nox1 expression, so other factors must compensate to regulate superoxide production.

23 October 2012 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
FLFelipe R. Lorenzo
Felipe R. Lorenzo
Chunzhang YangChunzhang Yang
Chunzhang Yang
MFMark Ng Tang Fui
Mark Ng Tang Fui
HVHariprasad Vankayalapati
Hariprasad Vankayalapati
ZZZhengping Zhuang
Zhengping Zhuang
JPJosef Prchal
Josef Prchal

7 October 2016 in BMC Medicine
Verified
Journal Article
Open access
PDF file
MFMark Ng Tang Fui
Mark Ng Tang Fui
LPLuke Prendergast
Luke Prendergast
PDPhilippe Dupuis
Philippe Dupuis
MRManjri Raval
Manjri Raval
BSBoyd J. Strauss
Boyd J. Strauss
MGMathis Grossmann
Mathis Grossmann
Whether testosterone treatment has benefits on body composition over and above caloric restriction in men is unknown. We hypothesised that testosterone treatment augments diet-induced loss of fat mass and prevents loss of muscle mass. We conducted a randomised double-blind, parallel, placebo controlled trial at a tertiary referral centre. A total of 100 obese men (body mass index ≥ 30 kg/m2) with a total testosterone level of or below 12 nmol/L and a median age of 53 years (interquartile range 47–60) receiving 10 weeks of a very low energy diet (VLED) followed by 46 weeks of weight maintenance were randomly assigned at baseline to 56 weeks of 10-weekly intramuscular testosterone undecanoate (n = 49, cases) or matching placebo (n = 51, controls). The main outcome measures were the between-group difference in fat and lean mass by dual-energy X-ray absorptiometry, and visceral fat area (computed tomography). A total of 82 men completed the study. At study end, compared to controls, cases had greater reductions in fat mass, with a mean adjusted between-group difference (MAD) of –2.9 kg (–5.7 to –0.2; P = 0.04), and in visceral fat (MAD –2678 mm2; –5180 to –176; P = 0.04). Although both groups lost the same lean mass following VLED (cases –3.9 kg (–5.3 to –2.6); controls –4.8 kg (–6.2 to –3.5), P = 0.36), cases regained lean mass (3.3 kg (1.9 to 4.7), P < 0.001) during weight maintenance, in contrast to controls (0.8 kg (–0.7 to 2.3), P = 0.29) so that, at study end, cases had an attenuated reduction in lean mass compared to controls (MAD 3.4 kg (1.3 to 5.5), P = 0.002). While dieting men receiving placebo lost both fat and lean mass, the weight loss with testosterone treatment was almost exclusively due to loss of body fat. clinicaltrials.gov, identifier NCT01616732 , registration date: June 8, 2012

28 December 2016 in International Journal of Obesity
Verified
Journal Article
Closed access
MFM Ng Tang Fui
M Ng Tang Fui
RHR Hoermann
R Hoermann
LPLuke Prendergast
Luke Prendergast
JZJ D Zajac
J D Zajac
MGM Grossmann
M Grossmann

11 December 2014 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
MGMathis Grossmann
Mathis Grossmann
RHRudolf Hoermann
Rudolf Hoermann
MFMark Ng Tang Fui
Mark Ng Tang Fui
JZJeffrey D. Zajac
Jeffrey D. Zajac
FIFranscesco L. Ierino
Franscesco L. Ierino
MRMatthew A. Roberts
Matthew A. Roberts